NRAS and cholangiocarcinoma: Given the widespread expression of SOX9 in fully developed Akt-YAP1 or Akt-NRAS CCA regions as well as poorly differentiated HCC regions (Figure 2B), we delivered SB-STOP(flf)−Cas9-sg-Sox9 along with the Akt-YAP1 or Akt-NRAS plasmid into OPN-CreERT2 mice to induce liver cancer.